Skip to content

Ultrasound With Subharmonic Imaging and Subharmonic Aided Pressure Estimation (SHAPE) to Identify Portal Hypertension

Invoking Subharmonics and Subharmonic Aided Pressure Estimation (SHAPE) for Identifying Portal Hypertension

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06797193
Enrollment
60
Registered
2025-01-28
Start date
2025-03-13
Completion date
2027-03-31
Last updated
2025-12-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Portal Hypertension

Brief summary

This clinical trial tests the how well an ultrasound with subharmonic imaging and the subharmonic aided pressure estimation (SHAPE) technique works in identifying portal hypertension (PH). An ultrasound takes pictures of the inside of the body by bouncing sound waves off organs. PH is high blood pressure in the vein that carries blood to the liver from the stomach, small and large intestines, spleen, pancreas, and gallbladder. The complications associated with PH are clear only after severe liver dysfunction or liver cirrhosis develops and are accompanied by relatively high mortality rates (20-70% mortality within 2 years). Thus, identifying PH earlier is beneficial. The hepatic venous pressure gradient (HVPG) obtained using an invasive catheterization procedure remains the standard for assessing PH. However, using this invasive procedure to assess PH prevents frequent pressure monitoring. Thus, a noninvasive technique to estimate PH is beneficial not only for diagnosis but also for monitoring treatment and disease progression. The SHAPE technique is a noninvasive ultrasound-based imaging technique that can estimate pressure with an ultrasound contrast agent. A noninvasive technique using an ultrasound with subharmonic imaging and the SHAPE technique may work in identifying PH.

Detailed description

PRIMARY OBJECTIVES: I. To evaluate if SHAPE with perflutren lipid microspheres (Definity) microbubbles identifies patients with clinically significant PH. II. To evaluate if addition of subharmonic imaging-based perfusion parameters derived from time intensity curves and shear wave elastography (SWE) measurements increase the diagnostic confidence of detecting PH. OUTLINE: Patients receive Definity intravenously (IV) once on study. Additionally, patients undergo ultrasound with and without SHAPE technique as well as standard of care liver biopsy on study. After completion of study intervention, patients are followed up for 30 minutes.

Interventions

OTHERElectronic Health Record Review

Ancillary studies

PROCEDURELiver Biopsy

Undergo liver biopsy

OTHERMedical Device Usage and Evaluation

Undergo ultrasound with SHAPE technique

PROCEDUREUltrasound Imaging

Undergo ultrasound

Sponsors

Mayo Clinic
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Provide signed and dated informed consent form * Willing to comply with all study procedures * Adult patients (age of 18 years or older) * If a female of child-bearing potential, must have a negative pregnancy test * Be scheduled for HVPG measurement

Exclusion criteria

* Patients who are unable to provide consent * Females who are pregnant or nursing * Patients with known or suspected hypersensitivity to perflutren lipid microsphere or its components, such as polyethylene glycol (PEG)

Design outcomes

Primary

MeasureTime frameDescription
Clinically significant portal hypertension (PH)Baseline (at time of ultrasound)Will evaluate if subharmonic aided pressure estimation with Definity microbubbles identifies patients with clinically significant PH.
Diagnostic confidenceBaseline (at time of ultrasound)Will evaluate if the addition of subharmonic imaging-based perfusion parameters increase the diagnostic confidence of detecting PH.

Countries

United States

Contacts

Primary ContactClinical Trials Referral Office
mayocliniccancerstudies@mayo.edu855-776-0015
Backup ContactBea Hartke
507-284-9653

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026